Edition:
United Kingdom

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

1.27USD
8:23pm GMT
Change (% chg)

$0.01 (+0.79%)
Prev Close
$1.26
Open
$1.26
Day's High
$1.32
Day's Low
$1.23
Volume
38,577
Avg. Vol
91,916
52-wk High
$2.92
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Infinity Pharma Earns $22 Mln Payment From Verastem Oncology For FDA Approval Of Copiktra (Duvelisib) And Updates 2018 Financial Guidance
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS EARNS $22 MILLION PAYMENT FROM VERASTEM ONCOLOGY FOR FDA APPROVAL OF COPIKTRA™ (DUVELISIB) AND UPDATES 2018 FINANCIAL GUIDANCE.INFINITY PHARMACEUTICALS INC - EXPECTS NET LOSS FOR 2018 TO RANGE FROM $10 MILLION TO $20 MILLION..INFINITY PHARMACEUTICALS - EXPECTS TO END 2018 WITH YEAR-END CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES BALANCE RANGING $50 MILLION TO $60 MILLION.INFINITY PHARMACEUTICALS - SEES EXISTING CASH, CASH EQUIVALENTS, AVAILABLE-FOR-SALE SECURITIES TO BE ADEQUATE TO SATISFY CAPITAL NEEDS INTO 2020.  Full Article

Arcus Biosciences, Infinity Pharmaceuticals Enter Clinical Collaboration To Evaluate Two Triple Combination Therapies In Selected Tumor Types
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Infinity Pharmaceuticals Inc ::ARCUS BIOSCIENCES AND INFINITY PHARMACEUTICALS ANNOUNCE CLINICAL COLLABORATION TO EVALUATE LEAD PROGRAMS IN TRIPLE-COMBINATION STUDIES.INFINITY PHARMACEUTICALS - CO, ARCUS BIOSCIENCES ENTER CLINICAL COLLABORATION TO EVALUATE TWO TRIPLE COMBINATION THERAPIES IN SELECTED TUMOR TYPES.INFINITY PHARMACEUTICALS INC - COLLABORATION WILL EVALUATE IPI-549 IN COMBINATION WITH AB928 AND AB122.INFINITY PHARMACEUTICALS - COLLABORATION TO ALSO EVALUATE IPI-549 WITH AB928 & CHEMOTHERAPY IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER/OVARIAN CANCER.INFINITY PHARMACEUTICALS INC - INFINITY AND ARCUS WILL SHARE EQUALLY EXPENSES RELATED TO FOUR TRIPLE-COMBINATION COHORTS.INFINITY PHARMACEUTICALS INC - TOPLINE DATA FROM THE STUDIES ARE EXPECTED IN 2019.  Full Article

Infinity Pharmaceuticals Q1 Loss Per Share $0.18
Tuesday, 8 May 2018 

May 8 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, DILUTED LOSS PER COMMON SHARE WAS $0.18 - SEC FILING.Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.INFINITY PHARMA - BELIEVES EXISTING CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES WILL BE ADEQUATE TO SATISFY FORECASTED OPERATING NEEDS INTO Q3 2019.INFINITY PHARMACEUTICALS - EXPECTS TO CONTINUE TO "INCUR SIGNIFICANT OPERATING LOSSES FOR THE FORESEEABLE FUTURE".  Full Article

Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing
Monday, 30 Apr 2018 

April 30 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 1.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article

BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10
Thursday, 12 Apr 2018 

April 12 (Reuters) - Biotechnology Value Fund LP::BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING.BVF PARTNERS SAYS PURCHASED INFINITY PHARMACEUTICALS SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​.INFINITY PROVIDES UPDATE ON IPI-549 PHASE 1/1B STUDY, 2018 GOALS AND FINANCIAL GUIDANCE.INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION​.INFINITY PHARMACEUTICALS INC - EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION.INFINITY PHARMACEUTICALS INC - ‍INFINITY ENDED 2017 WITH APPROXIMATELY $57.6 MILLION IN CASH AND INVESTMENTS​.  Full Article

Infinity Q3 loss per share $0.14
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity provides company update and reports third quarter 2017 financial results.Q3 loss per share $0.14.Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Q3 revenue $6.0 million.Q3 revenue view $14.7 million -- Thomson Reuters I/B/E/S.Infinity Pharmaceuticals Inc - ‍infinity expects net loss for 2017 to range from $40 million to $50 million​.Infinity Pharmaceuticals - ‍expects to end 2017 with a cash, cash equivalents and available-for-sale securities balance ranging from $40 million to $50 million​.  Full Article

UPDATE 1-Roche scores win in slowing aggressive type of breast cancer

* Trailing rivals, Roche seeking immunotherapy niches (Adds comments from lead study author, details on PD-L1 subgroup)